# LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients

Study · id `cardio:ct-nct06657326` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06657326](<https://clinicaltrials.gov/study/NCT06657326>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06657326

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 444 participants.

## Technical summary

Registry record NCT06657326. Randomized; single masking; primary purpose treatment. Start 2024-12-18 (actual); primary completion 2026-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 444 participants (planned count; ClinicalTrials.gov record NCT06657326, source copy `cardio:ctgov-nct06657326-2025-06-05`, retrieved 2026-10-26)
- Started: 2024-12-18 (actual) (ClinicalTrials.gov record NCT06657326, source copy `cardio:ctgov-nct06657326-2025-06-05`, retrieved 2026-10-26)
- Primary completion: 2026-08 (anticipated) (ClinicalTrials.gov record NCT06657326, source copy `cardio:ctgov-nct06657326-2025-06-05`, retrieved 2026-10-26)
- Completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT06657326, source copy `cardio:ctgov-nct06657326-2025-06-05`, retrieved 2026-10-26)
- Countries: Malaysia (ClinicalTrials.gov record NCT06657326, source copy `cardio:ctgov-nct06657326-2025-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06657326-2025-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients
- Condition: Coronary Artery Disease
- Condition: Chronic Stable Angina
- Condition: Unstable Angina
- Condition: Silent Ischemia
- Condition: Acute Coronary Syndrome
- Intervention (Device): BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent
- Intervention (Device): BioFreedom™ stainless steel Biolimus A9™-coated stent
- Lead sponsor: Biosensors Europe SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry lists this organization as the lead sponsor: Biosensors Europe SA (`cardio:org-biosensors-europe-sa`)

## Provenance

Content hash: e460b3c6cfa06f525332ece32486e6b8d9e8af714a28a4d0ba0f3a7b331cad72
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
